The Case Against the Routine Use of Radiation Therapy in Advanced-Stage Hodgkin's Disease

References

• Lister T A, Crowther D, Sutcliffe S B, et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. J Clin Oncol 1989; 7: 1630–1636
   PubMed Web of Science ®Google Scholar
• Mauch P, Goodman R, Hellman S. The significance of mediastinal involvement in early stage Hodgkin's disease. Cancer 1978; 42: 1039–1045
   PubMed Web of Science ®Google Scholar
• Prosnitz L R, Curtis A M, Knowlton A H, et al. Supradiaphragmatic Hodgkin's disease: Significance of large mediastinal masses. Int J Radiat Oncol Biol Phys 1980; 6: 809–813
   PubMed Web of Science ®Google Scholar
• Fuller L M, Madoc-Jones H, Hagemeister F B, et al. Further follow up results of treatment in 90 laparotomy-negative stage I and II Hodgkin's disease patients: Significance of mediastinal and non-mediastinal presentations. Int J Radiat Oncol Biol Phys 1980; 6: 799–808
   PubMed Web of Science ®Google Scholar
• Lee C KK, Bloomfield C D, Goldman A I, et al. Prognostic significance of mediastinal involvement in Hodgkin' s disease treated with curative radiotherapy. Cancer 1980; 46: 2403–2409
   PubMed Web of Science ®Google Scholar
• Hoppe R T, Coleman C N, Cox R S, et al. The management of stage I-II Hodgkin's disease with irradiation alone or combined modality therapy: The Stanford experience. Blood 1982; 59: 455–465
   PubMed Web of Science ®Google Scholar
• Behar R A, Horning S J, Hoppe R T. Hodgkin's disease with bulky mediastinal involvement: Effective management with combined modality therapy. Int J Radiat Oncol Biol Phys 1993; 25: 771–776
   PubMed Web of Science ®Google Scholar
• Longo D L, Glatstein E, Duffey P L, et al. Radiation therapy versus combination chemotherapy in the treatment of early-stage Hodgkin's disease: Seven year results of a prospective randomized trial. J Clin Oncol 1991; 9: 906–917
   PubMed Web of Science ®Google Scholar
• Ekert H, Waters K D, Smith P J, et al. Treatment with MOPP or ChlVPP chemotherapy only for all stages of childhood Hodgkin's disease. J Clin Oncol 1988; 6: 1845–1850
   PubMed Web of Science ®Google Scholar
• Longo D L, Russo A, Duffey P L, et al. Treatment of advanced-stage massive mediastinal Hodgkin's disease: The case for combined modality treatment. J Clin Oncol 1991; 9: 227–235
   PubMed Web of Science ®Google Scholar
• Longo D L, Duffey P L, Young R C, et al. Conventional-dose salvage combination chemotherapy in patients relapsing with Hodgkin's disease after combination chemotherapy: The low probability for cure. J Clin Oncol 1992; 10: 210–218
   PubMed Web of Science ®Google Scholar
• Fabian C, Dahlberg S, Miller T, et al. Efficacy of low dose involved field (LDIF) XRT in producing and maintaining CR following PR induction with MOP-BAP chemotherapy in Hodgkin's disease: Results of Southwest Oncology Group study 7808. Proc Am Soc Clin Oncol 1989; 8: 253, (abstract 987)
   Google Scholar
• Vose J, Armitage J, Weisenburger D, et al. Ch1VPP-An effective and well-tolerated alternative to MOPP therapy for Hodgkin's disease. Am J Clin Oncol 1988; 11: 423–426
   PubMed Web of Science ®Google Scholar
• Klimo P, Connors J M. An update on the Vancouver experience in the management of advanced Hodgkin's disease treated with the MOPP/ABV hybrid program. Semin Hematol 1988; 25(Suppl 2)34–40
   PubMed Web of Science ®Google Scholar
• O'Reilly S E, Hoskins P, Klimo P, et al. MACOP-B and VACOP-B in diffuse large cell lymphomas and MOPP/ABV in Hodgkin's disease. Ann Oncol 1991; 2(Suppl 1)17–23
   PubMedGoogle Scholar
• Fischer J J, Papac R J. Theoretical considerations in combinations of localized and systemic therapy for neoplastic diseases. J Theor Biol 1972; 37: 105–114
   PubMed Web of Science ®Google Scholar
• Frei E, III, Luce J K, Gamble J F, et al. Combination chemotherapy in advanced Hodgkin's disease: Induction and maintenance of remission. Ann Intern Med 1973; 79: 376–382
   PubMed Web of Science ®Google Scholar
• Young R C, Canellos G P, Chabner B A, et al. Patterns of relapse in advanced Hodgkin's disease treated with combination chemotherapy. Cancer 1978; 42: 1001–1007
   PubMed Web of Science ®Google Scholar
• Prosnitz L R, Farber L R, Kapp D S, et al. Combined modality therapy for advanced Hodgkin's disease: 15-year follow-up data. J Clin Oncol 1988; 6: 603–612
   PubMed Web of Science ®Google Scholar
• Longo D L, Young R C, Wesley M, et al. Twenty years of MOPP therapy for Hodgkin's disease. J Clin Oncol 1986; 4: 1295–1306
   PubMed Web of Science ®Google Scholar
• Donaldson S S, Link M. P. Combined modality treatment with low-dose radiation and MOPP chemotherapy for children with Hodgkin's disease. J Clin Oncol 1987; 5: 742–749
   PubMed Web of Science ®Google Scholar
• Hudson M M, Greenwald C, Thompson E, et al. Efficacy and toxicity of multiagent chemotherapy and low-dose involved-field radiotherapy in children and adolescents with Hodgkin's disease. J Clin Oncol 1993; 11: 100–108
   PubMed Web of Science ®Google Scholar
• Brizel D M, Winer E P, Prosnitz L R, et al. Improved survival in advanced Hodgkin's disease with the use of combined modality therapy. Int J Radial Oncol Biol Phys 1990; 19: 535–542
   Web of Science ®Google Scholar
• Yahalom J, Ryu J, Straus D J, et al. Impact of adjuvant radiation on the patterns and rate of relapse in advanced-stage Hodgkin's disease treated with alternating chemotherapy combinations. J Clin Oncol 1991; 9: 2193–2201
   PubMed Web of Science ®Google Scholar
• Pavlovsky S, Santarelli M T, SackmannMuriel F, et al. Randomized trial of chemotherapy versus chemotherapy plus radiotherapy for stage III-IV A and B Hodgkin's disease. Ann Oncol 1992; 3: 533–537
   PubMed Web of Science ®Google Scholar
• Crowther D, Wagstaff J, Deakin D, et al. A randomized study comparing chemotherapy alone with chemotherapy followed by radiotherapy in patients with pathologically staged IIIA Hodgkin's disease. J Clin Oncol 1984; 2: 892–897
   PubMed Web of Science ®Google Scholar
• Click J, Rubin P, Tsiatis A, et al. Hodgkin' s disease stage IIIB and IV: Failure of radiation consolidation to improve survival compared to B-MOPP/ABVD: An ECOG study. Proc Am Soc Ther Radial Oncol 1987; 13(Suppl 1)91, (abstract)
   Google Scholar
• Click J, Tsiatis A, Chen M, et al. Improved survival with MOPP-ABVD compared to BCVPP ± radiotherapy (RT) for advanced Hodgkin's disease: 6-year ECOG results. Blood 1990; 76(Suppl 1)350a, (abstract 1392)
   Google Scholar
• Grozea P N, Depersio E J, Coltman C. A., Jr, . Chemotherapy alone versus combined modality therapy for stage III Hodgkin's disease: A five-year follow-up of a Southwest Oncology group study. Malignant Lymphomas and Hodgkin's Disease: Experimental and Therapeutic Advances, F. Cavalli, G Bonadonna, M Rozencweig, et al. Martinus Nijhoff Publishers, Boston 1985; 345–351
   Google Scholar
• Fabian C J, Mansfield C M, Dahlberg S, et al. Low-dose involved field radialion after chemotherapy in advanced Hodgkin disease: A Southwest Oncology Group randomized study. Ann Intern Med 1994; 120: 903–912
   PubMed Web of Science ®Google Scholar
• Yelle L, Bergsagel D, Basco V, et al. Combined modality therapy of Hodgkin's disease: 10-year results of National Cancer Inslilule of Canada clinical trials group multicenter clinical trial. J Clin Oncol 1991; 9: 1983–1993
   PubMed Web of Science ®Google Scholar
• Diehl V, Pfreundschuh M, Löffler M, et al. Chemotherapy vs. involved-field (IF) radiotherapy for consolidation of remission achieved with three double cycles of cyclophosphamide, vincristine, procarbazine, prednisone (COPP) and doxorubicin, bleomycin, vinblastine, dacarbazine (ABVD) for stages IIIB/IV Hodgkin's disease: A randomized trial of the German Hodgkin Study Group. Proc Am Soc Clin Oncol 1990; 9: 273, (abstract 1057)
   Google Scholar
• Longo D L, Young R C, DeVita V. T., Jr. Chemotherapy for Hodgkin's disease: The remaining challenges. Cancer Treat Rep 1982; 66: 925–936
   PubMedGoogle Scholar
• Kaplan H S. Evidence for a tumoricidal dose level in the radiotherapy of Hodgkin's disease. Cancer Res 1966; 26: 1221–1224
   PubMed Web of Science ®Google Scholar
• Prosnitz L R. Hodgkin's disease: The right dose. Int J Radiat Oncol Biol Phys 1990; 19: 803–804
   PubMed Web of Science ®Google Scholar
• Schewe K L, Reavis J, Kun L E, et al. Total dose, fraction size, and tumor volume in the local control of Hodgkin's disease. Int J Radiat Oncol Biol Phys 1988; 15: 25–28
   PubMed Web of Science ®Google Scholar
• Vijayakumar S, Myrianthopoulos L C. An updated dose-response analysis in Hodgkin's disease. Radiother Oncol 1992; 24: 1–13
   PubMed Web of Science ®Google Scholar
• Loeffler M, Ruhl U, Hasenclever D, et al. Irradiation with 20, 30 or 40 Gy is equally effective in non-bulky areas after two double cycles of COPP-ABVD polychemotherapy in intermediate stage Hodgkin's disease. Blood 1994; 84(Suppl 1)234a, (abstract 921)
   Google Scholar
• Maity A, Goldwein J W, Lange B, et al. Comparison of high-dose and low-dose radiation with and without chemotherapy for children with Hodgkin's disease: An analysis of the experience at the Children's Hospital of Philadelphia and the Hospital of the University of Pennsylvania. J Clin Oncol 1992; 10: 929–935
   PubMed Web of Science ®Google Scholar
• Lavey R S, Eby N L, Prosnitz L R. Impact on second malignancy risk of the combined use of radiation and chemotherapy for lymphomas. Cancer 1990; 66: 80–88
   PubMed Web of Science ®Google Scholar
• Tucker M A, Coleman C N, Cox R S, et al. Risk of second cancers after irealmenl for Hodgkin's disease. N Engl J Med 1988; 318: 76–81
   PubMed Web of Science ®Google Scholar
• Blayney D W, Longo D L, Young R C, et al. Decreasing risk of leukemia with prolonged follow-up after chemolherapy and radiotherapy for Hodgkin's disease. N Engl J Med 1987; 316: 710–714
   PubMed Web of Science ®Google Scholar
• Valagussa P, Santoro A, Fossati-Bellani F, et al. Sound acute leukemia and other malignancies following treatment for Hodgkin's disease. J Clin Oncol 1986; 4: 830–837
   PubMed Web of Science ®Google Scholar
• Andrieu J M, Ifrah N, Payen C, et al. Increased risk of secondary acute nonlymphocytic leukemia after extended-field radiation therapy combined with MOPP chemotherapy for Hodgkin's disease. J Clin Oncol 1990; 8: 1148–1154
   PubMed Web of Science ®Google Scholar
• Van Leeuwen F E, Klokman W J, Hagenbeek A, et al. Second cancer risk following Hodgkin's disease: A 20-year follow-up sludy. J Clin Oncol 1994; 12: 312–325
   PubMed Web of Science ®Google Scholar
• Meadows A T, Obringer A C, Marrero O, et al. Second malignant neoplasms following childhood Hodgkin's disease: Treatmenl and spleneclomy as risk factors. Med Pediatr Oncol 1989; 17: 477–484
   PubMedGoogle Scholar
• Hancock S L, Tucker M A, Hoppe R T. Breast cancer after treatment of Hodgkin's disease. J Nail Cancer Insl 1993; 85: 25–31
   PubMed Web of Science ®Google Scholar
• Hancock S L, Donaldson S S, Hoppe R T. Cardiac disease following Ireatmenl of Hodgkin's disease in children and adolecenls. J Clin Oncol 1993; 11: 1208–1215
   PubMed Web of Science ®Google Scholar
• Hancock S L, Tucker M A, Hoppe R T. Factors affecting late mortality from heart disease after treatment of Hodgkin's disease. JAMA 1993; 270: 1949–1955
   PubMed Web of Science ®Google Scholar